Get the Stockscreener App
3.269
1.84%
0.059
After Hours:
3.27
0.0010
+0.03%
Evoke Pharma Inc Stock (EVOK) Latest News
StockNews.com Begins Coverage on Evoke Pharma (NASDAQ:EVOK) - Defense World
Evoke Pharma stock hits 52-week low at $3.4 amid challenges - Investing.com Australia
Evoke Pharma stock hits 52-week low at $3.4 amid challenges By Investing.com - Investing.com South Africa
Market Cool On Evoke Pharma, Inc.'s (NASDAQ:EVOK) Revenues Pushing Shares 29% Lower - Simply Wall St
Evoke Pharma, Inc. (NASDAQ:EVOK) Just Reported And Analysts Have Been Cutting Their Estimates - Yahoo Finance
EVOKEvoke Pharma Inc Latest Stock News & Market Updates - StockTitan
Earnings call transcript: Evoke Pharma Q4 2024 reports strong sales growth - Investing.com Australia
Evoke Pharma’s Earnings Call Highlights Revenue Growth and Strategic Partnerships - TipRanks
Evoke Pharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Evoke Pharma Inc (EVOK) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic Growth Plans - Yahoo Canada Finance
Evoke Pharma Reports Strong Revenue Growth in 2024 - TipRanks
Evoke Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - Marketscreener.com
EVOKE PHARMA Earnings Results: $EVOK Reports Quarterly Earnings - Nasdaq
Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
Arbor Realty Trust Closes a $1.15 Billion Repurchase Facility to Unwind Two Outstanding Collateralized Loan Obligations - The Manila Times
Earnings Scheduled For March 13, 2025 - Benzinga
Gastroparesis Treatment Market Poised for Substantial Growth - openPR
Evoke Pharma to Report Fourth Quarter and Full Year 2024 Results on March 13, 2025 - GlobeNewswire
Evoke Pharma, Inc. to Announce Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025 - Nasdaq
When Will Evoke Pharma Share Its Latest Gimoti Sales Numbers? - StockTitan
Evoke Pharma (EVOK) to Release Quarterly Earnings on Wednesday - Defense World
Sanctuary Advisors LLC Sells 40,570 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) - Defense World
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by Sanctuary Advisors LLC - Defense World
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Sanctuary Advisors LLC - Defense World
Evoke Pharma (NASDAQ:EVOK) Stock Crosses Below 200 Day Moving Average – Should You Sell? - Defense World
Alliance Bioenergy Plus (OTCMKTS:ALLM) Shares Cross Below 200 Day Moving Average – Time to Sell? - Defense World
Evoke Pharma (NASDAQ:EVOK) Earns Sell Rating from Analysts at StockNews.com - Defense World
Evoke Pharma stock hits 52-week low at $3.49 amid challenges - Investing.com India
Evoke Pharma stock hits 52-week low at $3.49 amid challenges By Investing.com - Investing.com South Africa
Evoke Pharma, Inc. to Host Earnings Call - ACCESS Newswire
Investor Network: Evoke Pharma, Inc. to Host Earnings Call - ACCESS Newswire
Gastroparesis Drugs Market Forecast: Insights, Trends & Key - openPR
Diabetic Gastroparesis Treatment Market Future Business - openPR
Evoke Pharma (NASDAQ:EVOK) Now Covered by Analysts at StockNews.com - Armenian Reporter
Evoke Pharma adds pharma veteran to its board - Investing.com
Evoke Pharma adds pharma veteran to its board By Investing.com - Investing.com South Africa
Evoke Pharma appoints new director Greg Pyszcymuka - Investing.com
5 Top AI Stocks I'm Buying on the Dip - The Globe and Mail
Evoke Pharma appoints new director Greg Pyszcymuka By Investing.com - Investing.com South Africa
Evoke Pharma, Inc. Appoints Greg Pyszczymuka to Board of Directors, Strengthening Commercial Strategy - Nasdaq
Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors - GlobeNewswire
Can This New Board Member Transform Evoke Pharma's Commercial Success? - StockTitan
(EVOK) Investment Analysis and Advice - Stock Traders Daily
Geriatric Medicines Market Poised for Significant Expansion | - openPR
Gastric Motility Disorder Drug Market Witnessing High Demand | - openPR
Evoke Pharma (NASDAQ:EVOK) Coverage Initiated by Analysts at StockNews.com - Defense World
Gastroparesis Drugs Market: $6,662.35 Million by 2032, 4.4% CAGR - openPR
Gastroparesis Treatment Market Generated Opportunities, - openPR
Evoke Pharma (NASDAQ:EVOK) Now Covered by StockNews.com - Defense World
Loss-Making Evoke Pharma, Inc. (NASDAQ:EVOK) Set To Breakeven - Simply Wall St
0.19%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):